ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - amlodipine as besylate 5 mg; atorvastatin as calcium 20 mg - film coated tablets - amlodipine - caduet (amlodipine and atorvastatin ) is indicated in patients for whom treatment with both amlodipine and atorvastatin is apptopriate. amlodipine: - hypertension - chronic stable angina - vasospastic angina (prinzmetal's or variant angina). atorvastatin : - prevention of cardiovascular disease - heterozygous familial and nonfamilial hypercholesterolemia - elevated serum tg levels - primary dysbetalipoproteinemia - homozygous familial hypercholesterolemia - pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - amlodipine as besylate 5 mg; atorvastatin as calcium 40 mg - film coated tablets - amlodipine - caduet (amlodipine and atorvastatin ) is indicated in patients for whom treatment with both amlodipine and atorvastatin is apptopriate. amlodipine: - hypertension - chronic stable angina - vasospastic angina (prinzmetal's or variant angina). atorvastatin : - prevention of cardiovascular disease - heterozygous familial and nonfamilial hypercholesterolemia - elevated serum tg levels - primary dysbetalipoproteinemia - homozygous familial hypercholesterolemia - pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - amlodipine as besylate 5 mg; atorvastatin as calcium 80 mg - film coated tablets - amlodipine - caduet (amlodipine and atorvastatin ) is indicated in patients for whom treatment with both amlodipine and atorvastatin is apptopriate. amlodipine: - hypertension - chronic stable angina - vasospastic angina (prinzmetal's or variant angina). atorvastatin : - prevention of cardiovascular disease - heterozygous familial and nonfamilial hypercholesterolemia - elevated serum tg levels - primary dysbetalipoproteinemia - homozygous familial hypercholesterolemia - pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - amlodipine as besylate 10 mg; atorvastatin as calcium 10 mg - film coated tablets - amlodipine - caduet (amlodipine and atorvastatin ) is indicated in patients for whom treatment with both amlodipine and atorvastatin is apptopriate. amlodipine: - hypertension - chronic stable angina - vasospastic angina (prinzmetal's or variant angina). atorvastatin : - prevention of cardiovascular disease - heterozygous familial and nonfamilial hypercholesterolemia - elevated serum tg levels - primary dysbetalipoproteinemia - homozygous familial hypercholesterolemia - pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - amlodipine as besylate 10 mg; atorvastatin as calcium 20 mg - film coated tablets - amlodipine - caduet (amlodipine and atorvastatin ) is indicated in patients for whom treatment with both amlodipine and atorvastatin is apptopriate. amlodipine: - hypertension - chronic stable angina - vasospastic angina (prinzmetal's or variant angina). atorvastatin : - prevention of cardiovascular disease - heterozygous familial and nonfamilial hypercholesterolemia - elevated serum tg levels - primary dysbetalipoproteinemia - homozygous familial hypercholesterolemia - pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - amlodipine as besylate 10 mg; atorvastatin as calcium 40 mg - film coated tablets - amlodipine - caduet (amlodipine and atorvastatin ) is indicated in patients for whom treatment with both amlodipine and atorvastatin is apptopriate. amlodipine: - hypertension - chronic stable angina - vasospastic angina (prinzmetal's or variant angina). atorvastatin : - prevention of cardiovascular disease - heterozygous familial and nonfamilial hypercholesterolemia - elevated serum tg levels - primary dysbetalipoproteinemia - homozygous familial hypercholesterolemia - pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - amlodipine as besylate 10 mg; atorvastatin as calcium 80 mg - film coated tablets - amlodipine - caduet (amlodipine and atorvastatin ) is indicated in patients for whom treatment with both amlodipine and atorvastatin is apptopriate. amlodipine: - hypertension - chronic stable angina - vasospastic angina (prinzmetal's or variant angina). atorvastatin : - prevention of cardiovascular disease - heterozygous familial and nonfamilial hypercholesterolemia - elevated serum tg levels - primary dysbetalipoproteinemia - homozygous familial hypercholesterolemia - pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 20 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa

ישראל - עברית - Ministry of Health

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 40 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet other nonpharmacological measures alone have been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death due to non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and nor